Combination therapies improve the anticancer activities of retinoids in neuroblastoma

World Journal of Clinical Oncology

Volumn 6, Issue 6, 2015, Pages 212-215

  Cheung, Belamy B ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Combination therapies; Fenretinide; Histone deacetylase inhibitors; Neuroblastoma; Retinoids

Indexed keywords

EID: 84951923640     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i6.212     Document Type: Review

References (29)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216 [PMID: 12612655]
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120 [PMID: 17586306]
3. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211 [PMID: 20558371 DOI: 10.1056/NEJMra0804577]
4. Masetti R, Biagi C, Zama D, Vendemini F, Martoni A, Morello W, Gasperini P, Pession A. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma. Adv Ther 2012; 29: 747-762 [PMID: 22941525 DOI: 10.1007/ s12325-012-0047-3]
5. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Fenton RM. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 1992; 10: 1666-1673 [PMID: 1403049]
6. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-1039 [PMID: 8801164]
7. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41-55 [PMID: 11796231]
8. Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biol Ther 2002; 1: 614-620 [PMID: 12642682]
9. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Longterm results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cisretinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007-1013 [PMID: 19171716 DOI: 10.1200/JCO.2007.13.8925]
10. Germain P, Iyer J, Zechel C, Gronemeyer H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 2002; 415: 187-192 [PMID: 11805839]
11. Sogno I, Venè R, Sapienza C, Ferrari N, Tosetti F, Albini A. Antiangiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res 2009; 181: 71-76 [PMID: 19213559]
12. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 91: 1138-1146 [PMID: 10393722]
13. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001; 6: 377-388 [PMID: 11483862]
14. Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 2008; 62: 655-665 [PMID: 18066548]
15. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res 2011; 17: 6858-6866 [PMID: 21908574 DOI: 10.1158/1078-0432. CCR-11-0995]
16. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24: 3423-3430 [PMID: 16849757]
17. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity in vivo. Br J Cancer 2009; 100: 758-763 [PMID: 19259094 DOI: 10.1038/sj.bjc.6604932]
18. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287-299 [PMID: 12120280]
19. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39 [PMID: 16960145]
20. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 2011; 29: 451-455 [PMID: 21696296 DOI: 10.3109/07357907.2011.590568]
21. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007; 104: 17777-17782 [PMID: 17968018]
22. Epping MT, Meijer LA, Bos JL, Bernards R. UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res 2009; 7: 1861-1870 [PMID: 19843631 DOI: 10.1158/1541-7786.MCR-09-0187]
23. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K. Expressionbased screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA 2008; 105: 9751-9756 [PMID: 18607002 DOI: 10.1073/pnas.0710413105]
24. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007; 6: 70-81 [PMID: 17237267]
25. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008; 87: 133-141 [PMID: 18060600]
26. Raif A, Marshall GM, Bell JL, Koach J, Tan O, D'andreti C, Thomas W, Sekyere E, Norris M, Haber M, Kavallaris M, Cheung BB. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. Cancer Lett 2009; 277: 82-90 [PMID: 19147277 DOI: 10.1016/j.canlet.2008.11.030]
27. De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007; 6: 1425-1432 [PMID: 17431121]
28. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28: 3623-3629 [PMID: 20606092 DOI: 10.1200/JCO.2009.25.9119]
29. Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Mol Oncol 2015; 9: 1484-1500 [PMID: 25963741 DOI: 10.1016/j.molonc.2015.04.005]